Journal
FRONTIERS IN PEDIATRICS
Volume 8, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fped.2020.00173
Keywords
Ceftolozane; tazobactam (C; T); cystic fibrosis-CF; children; pulmonary exacerbation; Pseudomonas aeruginosa
Categories
Ask authors/readers for more resources
Ceftolozane-tazobactam is a novel fifth-generation cephalosporin/beta-lactamase inhibitor combination recently approved for treatment of both complicated intra-abdominal and urinary tract infections in adults. Considering its potent bactericidal activity against Pseudomonas aeruginosa, it might represent an important option also for treating children with exacerbations of cystic fibrosis due to Pseudomonas aeruginosa when other alternative treatments have been exhausted. We hereby review available data on the use of ceftolozane-tazobactam in children, focusing on cystic fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available